asenapine
- Generic Name
- asenapine
- Brand Names
- Saphris, Secuado, Sycrest
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16ClNO
- CAS Number
- 65576-45-6
- Unique Ingredient Identifier
- JKZ19V908O
- Background
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as ...
- Indication
适用于成人精神分裂症和双相情感障碍患者的治疗。
- Associated Conditions
- Bipolar 1 Disorder, Mixed manic depressive episode, Schizophrenia, Acute Manic episode
- Associated Therapies
- Maintenance therapy
3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 489
- Registration Number
- NCT00159796
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 417
- Registration Number
- NCT00156117
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 277
- Registration Number
- NCT00151424
40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 77
- Registration Number
- NCT00145509
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 468
- Registration Number
- NCT00145496
12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 326
- Registration Number
- NCT00145470
9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 504
- Registration Number
- NCT00143182
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath